INBX · Inhibrx Biosciences Inc
United States · RS rating 54 · As of 2026-10-14
| Price | 85.26 USD |
|---|---|
| 1-day change | -2.1% |
| RS rating (overall / 1M / 3M / 12M) | 54 / 12 / 46 / 97 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 41 / 39 / 43 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +7.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +39.9% |
| Market cap (USD) | $1.8B |